CTI BioPharma Corp (fka CTIC)

[corner]

overreaction fear and perception


if what is advanced in portfolios as cancer products is true and not and arnaque


it s the best value in the cancer fields and biotechnology and despite all the past failures and delays .. it seems and strongly believe it still offers a real real value and huge upside potential

for the moment the market should digest today s news which in fact is generating 60 millions or more exactly abt 55 millions dol with a burnout needed for the next 12 months of 4 millions doll i t is really funded with the potential of pixantrone s europe revenues of more than 200 millions dol and the opaxio in phase 3 underway in additional to the latest big potential of it s latest acquisitions and may be a buyout or partnership in the tunnel.... it requires very little to start a cataclyst in the upside and massive short covering or even a massive squeeze ... the float is very small and the volume is huge .. today abt 23 millions sh on abt 55 millions shares


this company with so many deceptions and delays co9uld be one of the best player in the biotechnology field

in addition to all above a success of pixantrone in europe should secure without any hesitation the FDA approval and lead tio an explosion in the months aheadéé